7:30 PM - 8:00 PM: Dinner and Registration
8:00 PM - 8:10 PM: Welcome and Introduction
8:10 PM - 8:40 PM: Current Practice: CDK4/6 Inhibitors in the Management of HR+/HER2- MBC – Joyce O’Shaughnessy, MD
8:40 PM - 9:05 PM: Open Questions: The Evolving Role of PI3K Pathway Blockade in the Treatment of HR+/HER2- MBC – Sara Hurvitz, MD, FACP
9:05 PM - 9:25 PM: Future Directions: Exploring the Next Frontier for HR+/HER2- MBC – Matthew P. Goetz, MD
9:25 PM - 9:30 PM: Final Panel Discussion and Audience Question and Answer Session
Date / Time
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
US Oncology Network
Matthew Goetz, MD
Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Women's Cancer Program
Department of Medical Oncology
Sara Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in selecting individualized treatment for patients with hormone receptor–positive breast cancer.
This program is intended for physicians and other healthcare providers who care for patients with breast cancer.
- Discuss the mechanisms of endocrine resistance in breast cancer and the rationale for different therapeutic targets to overcome this resistance
- Evaluate available clinical data on abemaciclib, palbociclib, and ribociclib as part of current treatment algorithms for patients with de novo or recurrent HR-positive, HER2-negative MBC
- Describe current therapeutic strategies and ongoing clinical trials of novel CDK4/6 inhibitor–based combinations for both early-stage and HR-positive, HER2-negative MBC
- Summarize promising investigational treatment options after disease progression on endocrine and/or CDK4/6 inhibitor–based therapy
- Identify potential biomarkers of sensitivity to CDK4/6 inhibitors in patients with breast cancer
- Manage toxicities specific to agents used in the treatment of HR-positive breast cancer
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.